Longeveron Inc Ordinary Shares - Class A LGVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LGVN is a good fit for your portfolio.
News
-
Longeveron to Present at the Planet MicroCap Showcase
-
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
-
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
-
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
-
Longeveron Announces Closing of $5.2 Million Public Offering
-
Longeveron Announces Pricing of $5.25 Million Public Offering
-
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
-
Longeveron Announces 1-for-10 Reverse Stock Split
Trading Information
- Previous Close Price
- $1.72
- Day Range
- $1.60–1.72
- 52-Week Range
- $1.60–44.00
- Bid/Ask
- $1.64 / $1.69
- Market Cap
- $8.01 Mil
- Volume/Avg
- 322,085 / 2.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.57
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
- Website
- https://www.longeveron.com
Comparables
Valuation
|
Metric
|
LGVN
|
EQRX
|
PMVP
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.68 | 0.97 | 0.39 |
Price/Sales | 5.57 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
LGVN
EQRX
PMVP
Financial Strength
|
Metric
|
LGVN
|
EQRX
|
PMVP
|
|---|---|---|---|
Quick Ratio | 1.41 | 18.43 | 14.47 |
Current Ratio | 1.50 | 18.78 | 14.78 |
Interest Coverage | — | — | — |
Quick Ratio
LGVN
EQRX
PMVP
Profitability
|
Metric
|
LGVN
|
EQRX
|
PMVP
|
|---|---|---|---|
Return on Assets (Normalized) | −104.65% | −15.72% | −23.12% |
Return on Equity (Normalized) | −153.29% | −16.71% | −25.57% |
Return on Invested Capital (Normalized) | −128.91% | −21.31% | −27.79% |
Return on Assets
LGVN
EQRX
PMVP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cqjbqtrqpk | Kxjs | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hrdswmq | Zrtkvyn | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kfysvtny | Wtywdch | $99.5 Bil | |
MRNA
| Moderna Inc | Qdgsjmgzh | Lwcvv | $38.8 Bil | |
ARGX
| argenx SE ADR | Rtdjjgjsc | Ytcd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gvnwgpl | Plrf | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jbjchkln | Gstcyv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ydrynjxh | Vgjgwb | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cpspdfnrp | Kgqwb | $12.5 Bil | |
INCY
| Incyte Corp | Ymdwxwj | Gjlxpkp | $11.6 Bil |